Kane Biotech’s revyve Wound Care Tech Gains Traction in Military Medicine
Event summary
- Kane Biotech presented revyve antimicrobial wound care research at the Military Health System Research Symposium (MHSRS) on August 3-5, 2026.
- The presentation, 'Broad-Spectrum, Cavity-Filling Antimicrobial Gel Spray to Address Prolonged Field Care Wound Challenges,' was authored by Kane Biotech’s Drs. Huizinga, Sailer, and Visvalingam and presented by Lt. Col. Steven L.A. Jeffery.
- Kane Biotech engaged with researchers interested in exploring revyve’s potential in military and prolonged field care settings.
- revyve Antimicrobial Wound Gel Spray is FDA 510(k) cleared and Health Canada approved.
The big picture
Kane Biotech’s presentation at MHSRS highlights the growing interest in advanced wound care solutions for military and prolonged field care settings. The focus on antimicrobial and antibiofilm capabilities aligns with broader industry trends addressing antibiotic resistance and complex wound management. Military healthcare channels could represent a significant long-term opportunity for revyve, given the unique challenges of wound care in austere environments.
What we're watching
- Military Adoption
- How quickly Kane Biotech can secure partnerships or contracts with military healthcare systems to validate revyve’s efficacy in field settings.
- Clinical Validation
- Whether the planned clinical research will produce compelling data to support broader adoption in complex wound management.
- Commercial Expansion
- The pace at which Kane Biotech can expand revyve’s commercialization beyond military applications into civilian and government healthcare channels.
Related topics